| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01229410 | Vitrectomy | Drug: 400 g Brimonidine Tartrate Implant|Drug: 200 g Brimonidine Tartrate Implant | Allergan | Phase 1 | 2010-12-01 | 2013-07-02 |
| NCT02003534 | Glaucoma, Open-Angle|Ocular Hypertension | Drug: 0.15% Brimonidine Tartrate | Allergan | Phase 4 | 2010-07-01 | 2014-06-24 |
| NCT02039765 | Hyperemia | Drug: Brimonidine tartrate | Bausch & Lomb Incorporated|ORA, Inc. | Phase 1 | 2014-02-01 | 2014-03-28 |
| NCT02856919 | Chronic Persistent Vascular Facial Erythema | Drug: brimonidine tartrate | Galderma Brasil Ltda.|Eurotrials Brasil Consultores Cientificos Ltda | Phase 4 | 2016-06-01 | 2016-08-02 |
| NCT02568111 | Relapsing-Remitting Multiple Sclerosis (RRMS) | Drug: peginterferon beta-1a|Drug: brimonidine tartrate|Drug: Vehicle Gel | Biogen | Phase 4 | 2016-02-01 | 2016-04-21 |
| NCT00800423 | Corneal Edema|Visual Acuity | Drug: Brimonidine Tartrate 0.2%|Drug: Timolol maleate 0.5% | Rabin Medical Center | Phase 3 | 2009-01-01 | 2008-12-01 |
| NCT00658619 | Macular Degeneration | Drug: 400 g Brimonidine Tartrate Implant|Drug: 200 g Brimonidine Tartrate Implant|Other: Sham (no implant) | Allergan | Phase 2 | 2008-05-01 | 2013-03-13 |
| NCT01959230 | Hyperemia | Drug: Brimonidine Tartrate|Drug: Vehicle | Bausch & Lomb Incorporated|ORA, Inc. | Phase 3 | 2013-11-01 | 2014-07-24 |
| NCT02761174 | Telangiectasias | Drug: Brimonidine|Other: IPL+air-cooling | Merete Haedersdal|Skinperium, Christine Dierickx|Ellipse A/S Agern All 11, 2970 Hrsholm|Bispebjerg Hospital | Phase 4 | 2016-03-01 | 2016-05-02 |
| NCT00697541 | Erythematous Rosacea | Drug: 0.18% COL-118 facial gel (1.8 mg brimonidine)|Drug: 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop)|Drug: Advanced Eye Relief|Drug: COL-118 facial gel vehicle | Galderma | Phase 2 | 2008-05-01 | 2014-08-06 |
| NCT01959243 | Hyperemia | Drug: Brimonidine Tartrate|Drug: Vehicle | Bausch & Lomb Incorporated|ORA, Inc. | Phase 3 | 2014-02-01 | 2014-07-24 |
| NCT00972374 | Rhegmatogenous Macula-off Retinal Detachment | Drug: 400 ug Brimonidine Implant|Drug: 200 ug Brimonidine Implant|Other: Sham (no implant) | Allergan | Phase 2 | 2009-11-01 | 2013-03-13 |
| NCT02249065 | Rosacea | Drug: Brimonidine | Galderma Laboratories, L.P. | Phase 4 | 2014-09-01 | 2016-01-20 |
| NCT02818816 | Prostate Cancer | Drug: brimonidine tartrate 0.2%|Other: Carboxymethylcellulose Eye Drops | University Health Network, Toronto | Phase 4 | 2016-07-01 | 2016-07-27 |
| NCT01675609 | Ocular Redness | Drug: Placebo|Drug: Brimonidine tartrate 0.025% | Eye Therapies, LLC | Phase 2 | 2012-08-01 | 2014-07-28 |
| NCT01687426 | Glaucoma and Ocular Hypertension | Drug: Brimonidine Tartrate 0.025%|Drug: Vehicle | Eye Therapies, LLC | Phase 1 | 2012-09-01 | 2012-12-21 |
| NCT01250236 | Impact of Brimonidine on the Cornea | Drug: brimonidine 0.1%|Drug: placebo | Augenarztpraxis Breisach | | 2010-12-01 | 2010-12-02 |
| NCT00457795 | Open-angle Glaucoma|Ocular Hypertension | Drug: brimonidine 0.1% (Alphagan P) | Allergan | Phase 4 | 2006-12-01 | 2011-10-18 |
| NCT02975557 | Dry Eye|Ocular Graft vs Host Disease|Meibomian Gland Dysfunction | Drug: Brimonidine 0.15%|Drug: Brimonidine 0.075%|Drug: Placebo | University of Illinois at Chicago | Phase 1|Phase 2 | 2016-05-01 | 2016-11-23 |
| NCT02659670 | Rosacea | Other: internet survey|Drug: brimonidine topical gel 0.33% | Wake Forest University Health Sciences | Phase 4 | 2016-01-01 | 2016-11-01 |
